Abstract
The FDA approved the first biotherapeutic (synthetic insulin) in 1982. Thirty-five years later, this novel class of pharmaceuticals has improved the quality of life for millions of individuals. While drug discovery of biotherapeutics and biosimilars was originally dominated by small biotechnology companies, today nearly every major pharmaceutical company in the world is engaged in this effort. Biotherapeutic programs present unique challenges to drug development , including generating supportive data to demonstrate safety and efficacy in the target population. Bioanalysis of traditional chemical pharmaceutics may be achieved after organic extraction from biological fluids, thus removing potentially interfering substances. Furthermore, strategic decisions based on the structure of the molecule often facilitates the development of an analytical method utilizing sensitive mechanical instrumentation. Biotherapeutics are often composed of amino acids whose functionality depends on complex structure. These compounds are measured via protein-protein interactions requiring unique reagents for each drug program. In this chapter, we describe these interactions and focus on the importance of generating and maintaining high-quality reagents, a process known as reagent lifecycle management .
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest. 1960;39:1157–75.
Shah VP. The history of bioanalytical method validation and regulation: Evolution of a guidance document on bioanalytical methods validation. AAPS J. 2007;9(1):E43–7.
Findlay JWA, Smith WC, Lee JW, Nordblom GD, Das I, DeSilva BS, et al. Validation of immunoassay for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal. 2000;21(6):1249–73.
Findlay JWA, Dillard RF. Appropriate calibration curve fitting in ligand binding assays. AAPS J. 2007;9(2):E260–7.
Findlay JWA. Specificity and accuracy data for ligand-binding assays for macromolecules should be interpreted with caution. AAPS J. 2008;10(3):433–4.
Findlay JWA. Specificity of bioanalytical methods for pharmacokinetic support of biological macromolecular therapeutics is important. Bioanalysis. 2011;3(6):567–9.
Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–7.
Baker M. Blame it on the antibodies. Nature. 2015;521:274–6.
Bowsher RR, Nowatzke W, Sailstad JM, Khan MU. Application of commercial research-grade biomarker assay in drug development: is it time to create ‘pharmaceutical-grade’ kits? Bioanalysis. 2012;4(20):2427–30.
Rup B, O’Hara D. Critical ligand binding reagent preparation/selection: when specificity depends on reagents. AAPS J. 2007;9(2):E148–55.
Bradbury A, Pluckthün A. Standardize antibodies used in research. Nature. 2015;518:27–9.
Kricka LJ. Human anti-animal antibody interferences in immunological assays. Clin Chem. 1999;45(7):942–56.
Schwickart M, Vainshtein I, Lee R, Schneider A, Liang M. Interference in immunoassays to support therapeutic antibody development in preclinical and clinical studies. Bioanalysis. 2014;6(14):1939–51.
Tate J, Ward G. Interferences in immunoassays. Clin Biochem Rev. 2004;25:105–20.
O’Hara DM, Theobald V, Egan AC, Usansky J, Krishna M, TerWee J, et al. Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents. AAPS J. 2012;14(2):316–28.
FDA, US Department of Health and Human Services. Draft guidance for industry: bioanalytical method validation (revised). [Online] September 2013. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM368107.pdf.
Spriggs F, Zhong Z, Safavi A, Darshana J, Dontha N, Kant A. et al. Ligand binding assays in the 21st century laboratory: Platforms. AAPS J. 2012;14:113–8.
Forster R, Bertoncello P, Keyes T. Electrogenerated chemiluminescence. Ann Rev Anal Chem. 2009;2:359–85.
Fang L, Lü Z, Wei H, Wang E. Quantitative electrochemiluminescence detection of proteins: Avidin-based sensor and tris(2,2′-bipyridine) ruthenium(II) label. Biosens Bioelectron. 2008;23:1645–51.
Hemmilä I, Laitala V. Progress in lanthanides as luminescent probes. J Fluoresc. 2005;15:529–42.
Yuan J, Wang G. Lanthanide complex-based fluorescence label for time-resolved fluorescence bioassay. J Fluoresc. 2005;15:559–68.
Daghestani H, Day B. Theory and applications of surface plasmon resonance, resonant mirror, resonant waveguide grating, and dual polarization interferometry. Biosens Bioelectron. 2010;10:9630–46.
Viswanathan C, Bansal S, Booth B, DeStefano A, Rose M, Sailstad J, et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res. 2007;24:1962–73.
Yohrling J. Ligand-binding assays: risk of using a platform supported by a single vendor. Bioanalysis. 2009;1:629–36.
Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res. 2006;23(2):312–28.
Arnold ME, Booth B, King L. Ray C workshop report: Crystal City VI—bioanalytical method validation for biomarkers. AAPS J. 2016; doi:10.1208/s12248-016-9946-6.
Booth B, Arnold ME, DeSilva B, Amaravadi L, Dudal S, Fluhler E, et al. Workshop report: Crystal City V—quantitative bioanalytical method validation and implementation: the 2013 revised FDA guidance. AAPS J. 2015;17(2):277–88.
Lowes S, Ackermann BL. AAPS and US FDA Crystal City VI workshop on bioanalytical method validation for biomarkers. Bioanalysis. 2016;8(3):163–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Nowatzke, W., Spriggs, F., Fitzgerald, V., Davis, A., Bowsher, R.R. (2017). Development and Maintenance of Critical Reagents for Ligand Binding Assays to Support Regulatory-Compliant Bioanalysis. In: Rocci Jr., M., Lowes, S. (eds) Regulated Bioanalysis: Fundamentals and Practice. AAPS Advances in the Pharmaceutical Sciences Series, vol 26. Springer, Cham. https://doi.org/10.1007/978-3-319-54802-9_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-54802-9_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-54800-5
Online ISBN: 978-3-319-54802-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)